VirBio
Develops immune-based medicines for chronic hepatitis delta, solid tumors, and HIV cure research.
Something off on this page? Send us feedback.
Profile
Builds clinical-stage immunology medicines rather than an owned commercial product franchise. The pipeline centers on tobevibart plus elebsiran for chronic hepatitis delta, PRO-XTEN masked T-cell engagers for solid tumors, and preclinical HIV antibody candidates, with revenue still tied mainly to collaborations, licenses, and grants.
Operates as a clinical-stage immunology company with a single reportable segment focused on discovering and developing medicines for serious infectious diseases and cancer. Current programs center on tobevibart plus elebsiran for chronic hepatitis delta, PRO-XTEN masked T-cell engagers for solid tumors, and HIV antibody candidates with the Gates Foundation.
The business is not built around owned product sales yet. Recent revenue came from license, collaboration, grant, and other sources, including the Norgine agreement covering commercial rights for the hepatitis delta combination in Europe, Australia, and New Zealand.
Execution depends on clinical readouts, partner rights, and access to external technology: elebsiran is licensed from Alnylam, the PRO-XTEN platform came from Sanofi, and Astellas holds rights for VIR-5500 in prostate cancer.
Company facts
Key statistics
Year to date +82.3% · Average volume (30d) 1.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 6, 2026 | Morgan Stanley | Target | $27 | $25 | |
| Jun 11, 2026 | Morgan Stanley | Reiterate | Overweight | $23 | $27 |
| May 8, 2026 | Morgan Stanley | Target | $24 | $23 | |
| Mar 4, 2026 | H.C. Wainwright | Target | $15 | $20 | |
| Feb 26, 2026 | Leerink Partners | Target | $20 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.33 | $0.47 | +41.3% | $135.9M | $238.9M | +75.8% | −3.73% |
| May 6, 2026Q1 FY26 | −$0.01 | −$0.85 | −8,400.0% | $55.5M | −$29.0K | −100.1% | −9.91% |
| Feb 23, 2026Q4 FY25 | −$0.42 | −$0.31 | +26.2% | $19.9M | $64.1M | +221.9% | +27.73% |
| Nov 5, 2025Q3 FY25 | −$0.70 | −$1.17 | −67.1% | $19.9M | $240.0K | −98.8% | −5.19% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.2M | $240.0K | $64.1M | −$29.0K | $238.9M | |
| Gross profit | −$114.6M | −$96.3M | −$151.2M | $430.6M | −$2.8M | $238.9M | |
| Operating income | −$139.5M | −$118.4M | −$173.4M | −$36.6M | −$133.2M | $73.5M | |
| Net income | −$121.0M | −$111.0M | −$163.1M | −$42.9M | −$125.7M | $80.1M | |
| Diluted EPS | −$0.88 | −$0.80 | −$1.17 | −$0.31 | −$0.85 | $0.47 | |
| Gross margin | -3,779.1% | -7,932.9% | -63,005.0% | 672.1% | — | 100.0% | |
| Operating margin | -4,602.5% | -9,754.3% | -72,267.9% | -57.1% | — | 30.7% |
Fiscal years (4-quarter sums)FY21 $1.09B · FY22 $1.62B · FY23 $86.2M · FY24 $74.2M · FY25 $68.6M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $528.6M · Total debt $93.3M · Total assets $1.21B · Shareholders' equity $982.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 168.65M · Float 128.76M · 76.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.68M | 12.26% | 13F | Aug 7, 2026 |
| SVF Endurance (Cayman) Ltd · 10 percent owner | 13.73M | 8.14% | Form 4 | Dec 3, 2025 |
| Robert Nelsen | 13.53M | 8.50% | 13D | Mar 3, 2026 |
| Arch Venture Management, LLC | 12.69M | 7.53% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 11.50M | 6.82% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 1, 2026 | Brent Sabatini | officer: SVP, Chief Accounting Officer | −379 | $9.45 |
| Jun 1, 2026 | Janet Napolitano | director | −3,200 | $9.45 |
| May 1, 2026 | Vicki L. Sato | director | −22,000 | $10.05 |
| Apr 6, 2026 | Marianne de Backer | director, officer: President and CEO | −72,559 | $9.16 |
| Apr 1, 2026 | Vicki L. Sato | director | −22,000 | $9.07 |
Peers
- Gilead Sciences
Approved HDV entry inhibitor sets the main CHD benchmark
- Mirum Pharmaceuticals
Late-stage anti-HBsAg antibody challenger in HDV
- Janux Therapeutics
Tumor-activated PSMA TCE rival in prostate cancer
- Amgen
Scaled BiTE and prostate TCE competitor in solid tumors
- GSK (ADR)
Phase 3 HBV functional-cure ASO overlaps the hepatitis axis
- Aligos Therapeutics
HBV and early HDV programs overlap the upstream liver-virus lane
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| VirBio | $10.83 | 0.00% | $1.83B | — | — | 6.0 | +19,582.5% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Mirum Pharmaceuticals | $97.46 | 0.00% | $5.94B | — | — | 9.6 | +37.9% |
| Janux Therapeutics | $18.10 | +0.50% | $1.10B | — | — | 34.5 | — |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| Aligos Therapeutics | $7.02 | +2.48% | $42.8M | — | — | 1.4 | +2,778.6% |
| Median | 21.4 | 16.0 | 6.0 | +10.2% |